public · ai application

Tempus AI (TEM) AI Stock Analysis

AI-driven precision medicine company using machine learning to analyze clinical and molecular data for cancer treatment decisions. This page combines the latest public signals, bubble-risk estimate, value evidence, and source-backed research for investors evaluating Tempus AI.

Bubble risk estimate

78/100

Confidence: medium

Value evidence

62/100

Checked: 2026-11-18

Coverage

Ticker: TEM

Market type: public

Confidence: medium

Scores are provisional research estimates, not price targets or recommendations.

Is Tempus AI stock a buy or a bubble?

The score does not produce a buy or sell recommendation. It shows how much risk is attached to current expectations relative to the evidence currently available. Recent signals are mixed or neutral. Review the latest signals below, then compare the company with the broader AI Stock Bubble Index and the full scoring methodology.

2published signals
1risk-up signals
1counter-signals
2026-07-15latest signal date

What changed recently

Risk is not the same as value

Bubble risk measures how far expectations may be ahead of current evidence. Value evidence measures the strength of the underlying business signals.

Both scores are provisional and should be read with the confidence label and latest checked date.

Recent coverage for Tempus AI

No recent source-filtered company coverage is available yet. The next news update will retry company-specific queries.

How the company score has changed

DateBubble riskValue evidenceRecent signalsReason
2026-11-1878620No new signal; baseline carried forward.
2026-11-1778620No new signal; baseline carried forward.

Source-backed signals

Tempus AI
Risk upproduct release

Tempus AI announces $1.5B acquisition of cancer detection company Personalis

$1.5B acquisition

Tempus AI moved to acquire cancer genomics company Personalis for approximately $1.5 billion, expanding its genomic testing capabilities and clinical data moat.

Why it mattersThe acquisition accelerates Tempus's data advantage in precision medicine but increases integration risk and cash burn at a company already operating at a loss. Aggressive M&A at rich valuations is a hallmark of late-cycle AI enthusiasm.

Source: Eastmoney · Published 2026-07-15 · Checked 2026-07-30 · Confidence: medium

Tempus AI
Risk downrevenue

Tempus AI revenue grows 70% year-over-year, driven by AI-powered precision medicine demand

$1.36B TTM revenue, +70% YoY

Tempus AI reported approximately $1.36 billion in trailing twelve-month revenue, representing nearly 70% year-over-year growth, fueled by adoption of its AI-driven clinical and molecular data platform.

Why it mattersStrong top-line growth from a genuine AI application in healthcare provides real revenue evidence. However, the company remains unprofitable with negative free cash flow, and its $10.6 billion market cap implies a P/S ratio of approximately 7.8x, leaving room for valuation compression if growth decelerates.

Source: StockAnalysis · Published 2026-07-02 · Checked 2026-07-30 · Confidence: medium

Related ai application companies

Related research